Verrica Pharmaceuticals Enters Material Definitive Agreement
Ticker: VRCA · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $1.0680, $1.3350, $0.89, $0.8899, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Verrica Pharma signed a big deal, filing an 8-K today.
AI Summary
On November 20, 2024, Verrica Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for Verrica Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms, which are not fully detailed here.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 484-453-3300 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Verrica Pharmaceuticals?
The filing states that Verrica Pharmaceuticals Inc. entered into a material definitive agreement on November 20, 2024, but the specific terms and nature of this agreement are not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 20, 2024.
In which state is Verrica Pharmaceuticals Inc. incorporated?
Verrica Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for Verrica Pharmaceuticals Inc.?
The principal executive offices of Verrica Pharmaceuticals Inc. are located at 44 West Gay Street, Suite 400, West Chester, PA 19380.
What is the IRS Employer Identification Number for Verrica Pharmaceuticals Inc.?
The IRS Employer Identification Number for Verrica Pharmaceuticals Inc. is 46-3137900.
Filing Stats: 1,793 words · 7 min read · ~6 pages · Grade level 11.8 · Accepted 2024-11-21 16:55:29
Key Financial Figures
- $1.0680 — ts common stock at an exercise price of $1.0680 per share of common stock (the " Series
- $1.3350 — ts common stock at an exercise price of $1.3350 per share of common stock (the " Series
- $0.89 — at a combined public offering price of $0.89 per share of common stock and accompany
- $0.8899 — ying Series A and Series B Warrants (or $0.8899 per Pre-Funded Warrant and accompanying
- $0.0001 — ents the public offering price less the $0.0001 per share exercise price for each Pre-F
- $42.0 million — fering are expected to be approximately $42.0 million before deducting underwriting commissio
Filing Documents
- d769920d8k.htm (8-K) — 39KB
- d769920dex11.htm (EX-1.1) — 183KB
- d769920dex41.htm (EX-4.1) — 61KB
- d769920dex42.htm (EX-4.2) — 78KB
- d769920dex43.htm (EX-4.3) — 78KB
- d769920dex51.htm (EX-5.1) — 15KB
- d769920dex991.htm (EX-99.1) — 9KB
- g769920dsp91.jpg (GRAPHIC) — 4KB
- g769920g1121123843854.jpg (GRAPHIC) — 3KB
- 0001193125-24-263477.txt ( ) — 722KB
- vrca-20241120.xsd (EX-101.SCH) — 3KB
- vrca-20241120_lab.xml (EX-101.LAB) — 18KB
- vrca-20241120_pre.xml (EX-101.PRE) — 11KB
- d769920d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated November 20, 2024, by and between the Company and Jefferies LLC. 4.1 Form of Pre-Funded Warrant. 4.2 Form of Series A Warrant. 4.3 Form of Series B Warrant. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release. 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: November 21, 2024 /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer